



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Cetrelimab

Cat. No.:	HY-P99499
CAS No.:	2050478-92-5
Target:	PD-1/PD-L1; Interleukin Related; TNF Receptor
Pathway:	Immunology/Inflammation; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 ($K_d=1.72$ nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 ($IC_{50}s=111.7$ ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN- γ , IL-2, TNF- α level and inhibits tumor growth in vivo ^[1] .								
IC₅₀ & Target	PD-1/PD-L1, PD-1/PD-L2, IFN- γ , IL-2, and TNF- α ^[1]								
In Vitro	<p>Cetrelimab (0.01-30 nM; 5 d) binds to endogenous PD-1 on activated CD4⁺ and CD8⁺ T cells with $EC_{50}s$ of 0.16-0.22 μg/mL and 0.17-0.22 μg/mL, respectively^[1].</p> <p>Cetrelimab (0.01-30 μg/mL; 24 h) reverse PD-1-mediated suppression of TCR signaling in Jurkat-PD-1 NFAT reporter cells with CHO-K1 expressing PD-L1^[1].</p> <p>Cetrelimab (0.001-100 nM; 6 d) increases IFN-γ, IL-2, and TNF-α with $EC_{50}s$ of 0.08 ng/mL, 0.07 ng/mL, and 0.02 ng/mL, respectively^[1].</p> <p>Cetrelimab binds to PD-1 in cynomolgus with a K_d value of 0.9 nM^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Cetrelimab (10 mg/kg; i.p.; single dose) has antitumor efficacy, and decreases tumor volume in PD-1 knock-in (hPD-1KI) mice with MC38 tumor^[1].</p> <p>Cetrelimab (10 mg/kg; i.p.; once every 5 days for 30 d) results significant increases in peripheral blood CD8⁺ T cells in patient-derived xenograft (PDX) lung model in mice^[1].</p> <p>Cetrelimab (10-100 mg/kg; i.v.; once weekly for 5 weeks) has well tolerance in cynomolgus model^[1].</p> <p>Cetrelimab (0.1-10 mg/kg; i.v.; single dose, monitored for 57 d) shows an nonlinear pharmacokinetics (PK) in cynomolgus, possibly attributable to target-mediated drug deposition (TMDD)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>hPD-1KI model with mouse PD-1 ECD replaced by the human PD-1 ECD^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; single dose at day 7 after tumor implantation</td> </tr> <tr> <td>Result:</td> <td>hPD-1KI mice develop normally and have no immune abnormalities. Significantly lowered tumor volume at Day 21.</td> </tr> </table>	Animal Model:	hPD-1KI model with mouse PD-1 ECD replaced by the human PD-1 ECD ^[1]	Dosage:	10 mg/kg	Administration:	Intraperitoneal injection; single dose at day 7 after tumor implantation	Result:	hPD-1KI mice develop normally and have no immune abnormalities. Significantly lowered tumor volume at Day 21.
Animal Model:	hPD-1KI model with mouse PD-1 ECD replaced by the human PD-1 ECD ^[1]								
Dosage:	10 mg/kg								
Administration:	Intraperitoneal injection; single dose at day 7 after tumor implantation								
Result:	hPD-1KI mice develop normally and have no immune abnormalities. Significantly lowered tumor volume at Day 21.								

Animal Model:	Patient-derived xenograft (PDX) LG1306 lung model in mice ^[1]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; every 5 days for 6 cycles
Result:	Significantly reduced patient-derived tumor volume by 32%.

Animal Model:	Good Laboratory Practice (GLP) toxicity study in cynomolgus ^[1]
Dosage:	0, 10, 30, or 100 mg/kg
Administration:	Intravenous injection; once weekly for 5 weeks
Result:	Showed well tolerance in cynomolgus.

REFERENCES

[1]. DeAngelis N, et al. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. *Cancer Chemother Pharmacol.* 2022 Apr;89(4):515-527.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA